{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:57:55Z","timestamp":1770980275879,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clinthera.2021.01.017","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T05:02:55Z","timestamp":1614056575000},"page":"672.e1-672.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults"],"prefix":"10.1016","volume":"43","author":[{"given":"David","family":"Seiden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Dubow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.01.017_bib1","doi-asserted-by":"crossref","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","article-title":"Narcolepsy","volume":"3","author":"Kornum","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinthera.2021.01.017_bib2","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2021.01.017_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/sleep\/30.1.13","article-title":"The epidemiology of narcolepsy","volume":"30","author":"Longstreth","year":"2007","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2021.01.017_bib4","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1212\/WNL.58.12.1826","article-title":"Prevalence of narcolepsy symptomatology and diagnosis in the European general population","volume":"58","author":"Ohayon","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2021.01.017_bib5","first-page":"4654","article-title":"Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome","volume":"19","author":"Busardo","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2021.01.017_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1748-1716.2009.02012.x","article-title":"Hypocretin\/orexin and narcolepsy: new basic and clinical insights","volume":"198","author":"Nishino","year":"2010","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.clinthera.2021.01.017_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","article-title":"Recently approved and upcoming treatments for narcolepsy","volume":"34","author":"Thorpy","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2021.01.017_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2018.06.008","article-title":"Clinical characteristics and burden of illness in pediatric patients with narcolepsy","volume":"85","author":"Plazzi","year":"2018","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clinthera.2021.01.017_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419875622","article-title":"Recent advances in treatment for narcolepsy","volume":"12","author":"Barateau","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.clinthera.2021.01.017_bib10","series-title":"XYREM (Sodium Oxybate Oral Solution, CIII). Full Prescribing Information","year":"2018"},{"key":"10.1016\/j.clinthera.2021.01.017_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40120-016-0053-5","article-title":"Evaluation of quality of life in patients with narcolepsy treated with sodium oxybate: use of the 36-item Short-Form Health Survey in a clinical trial","volume":"5","author":"Bogan","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1016\/j.clinthera.2021.01.017_bib12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.sleep.2017.03.028","article-title":"Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice","volume":"35","author":"Drakatos","year":"2017","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2021.01.017_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsy128","article-title":"Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study","volume":"41","author":"Mayer","year":"2018","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2021.01.017_bib14","series-title":"XYWAV (Calcium, Magnesium, Potassium, and Sodium Oxybates). Full Prescribing Information","year":"2020"},{"key":"10.1016\/j.clinthera.2021.01.017_bib15","first-page":"106","article-title":"Narcolepsy in children and adults: a guide to improved recognition, diagnosis and management","volume":"7","author":"Morse","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.clinthera.2021.01.017_bib16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00434408","article-title":"The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review","volume":"71","author":"Parrott","year":"1980","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2021.01.017_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/pst.326","article-title":"Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion","volume":"8","author":"Hummel","year":"2009","journal-title":"Pharm Stat"},{"key":"10.1016\/j.clinthera.2021.01.017_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0091270003262795","article-title":"The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients","volume":"44","author":"Borgen","year":"2004","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2021.01.017_bib19","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/sleep\/27.7.1327","article-title":"A\u00a0pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy","volume":"27","author":"Mamelak","year":"2004","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2021.01.017_bib20","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5664\/jcsm.27994","article-title":"The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy","volume":"6","author":"Black","year":"2010","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.clinthera.2021.01.017_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/0091270002239707","article-title":"The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects","volume":"43","author":"Borgen","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2021.01.017_bib22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S2352-4642(18)30133-0","article-title":"Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation","volume":"2","author":"Plazzi","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.clinthera.2021.01.017_bib23","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/cts.12780","article-title":"Population and noncompartmental pharmacokinetics of sodium oxybate support weight-based dosing in children and adolescents with narcolepsy with cataplexy","volume":"13","author":"Chen","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.clinthera.2021.01.017_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00265954","article-title":"Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers","volume":"45","author":"Palatini","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2021.01.017_bib25","series-title":"Presented at: World Sleep; September 20\u201325","article-title":"Pharmacokinetics, relative bioavailability, and food effect of JZP-258 and sodium oxybate: results of two phase 1, open-label, randomised crossover studies in healthy volunteers [poster #148]","author":"Chen","year":"2019"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:27Z","timestamp":1758963267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821000448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0149291821000448"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}